Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

被引:319
作者
Gibson, SJ
Lindh, JM
Riter, TR
Gleason, RM
Rogers, LM
Fuller, AE
Oesterich, JL
Gorden, KB
Qiu, XH
McKane, SW
Noelle, RJ
Miller, RL
Kedl, RM
Fitzgerald-Bocarsly, P
Tomai, MA
Vasilakos, JP
机构
[1] 3M Ctr, 3M Pharmaceut, Dept Pharmacol, St Paul, MN 55144 USA
[2] 3M Ctr, Dept Biostat, St Paul, MN 55144 USA
[3] Dartmouth Coll, Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA
[4] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA
关键词
toll; TLR; TLR7; plasmacytoid DC; DC2; pDC; IFN; immune response modifier;
D O I
10.1016/S0008-8749(02)00517-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans. Recently, it was shown that plasmacytoid dendritic cells (pDC) are the primary interferon-producing cells in the blood in response to viral infections. Here, we characterize the activation of human pDC with the TLR7 agonists imiquimod and resiquimod. Results indicate that imiquimod and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood. Resiquimod-stimulated pDC also produce a number of other cytokines including TNF-alpha and IP-10. Resiquimod enhances co-stimulatory marker expression, CCR7 expression, and pDC viability. Resiquimod was compared throughout the study to the pDC survival factors, IL-3 and IFN-alpha; resiquimod more effectively matures pDC than either IL-3 or IFN-alpha alone. These results demonstrate that imidazoquinoline molecules directly induce pDC maturation as determined by cytokine induction, CCR7 and co-stimulatory marker expression and prolonging viability. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:74 / 86
页数:13
相关论文
共 47 条
[1]   Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848 [J].
Ahonen, CL ;
Gibson, SJ ;
Smith, RM ;
Pederson, LK ;
Lindh, JM ;
Tomai, MA ;
Vasilakos, JP .
CELLULAR IMMUNOLOGY, 1999, 197 (01) :62-72
[2]  
Austyn J M, 1998, Curr Opin Hematol, V5, P3, DOI 10.1097/00062752-199801000-00002
[3]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]   Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells [J].
Bauer, M ;
Redecke, V ;
Ellwart, JW ;
Scherer, B ;
Kremer, JP ;
Wagner, H ;
Lipford, GB .
JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :5000-5007
[6]   Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition [J].
Bauer, S ;
Kirschning, CJ ;
Häcker, H ;
Redecke, V ;
Hausmann, S ;
Akira, S ;
Wagner, H ;
Lipford, GB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9237-9242
[7]   EFFECTS OF THERAPY WITH AN IMMUNOMODULATOR (IMIQUIMOD, R-837) ALONE AND WITH ACYCLOVIR ON GENITAL HSV-2 INFECTION IN GUINEA-PIGS WHEN BEGUN AFTER LESION DEVELOPMENT [J].
BERNSTEIN, DI ;
MILLER, RL ;
HARRISON, CJ .
ANTIVIRAL RESEARCH, 1993, 20 (01) :45-55
[8]   Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment [J].
Bernstein, DI ;
Harrison, CJ ;
Tomai, MA ;
Miller, RL .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (06) :844-849
[9]   Maturation, activation, and protection of dendritic cells induced by double-stranded RNA [J].
Cella, M ;
Salio, M ;
Sakakibara, Y ;
Langen, H ;
Julkunen, I ;
Lanzavecchia, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (05) :821-829
[10]  
DEMEURE CE, 1994, J IMMUNOL, V152, P4775